Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis

Abstract Background Despite breakthroughs in treatment, metastatic castration-resistant prostate cancer (mCRPC) continues to pose a substantial problem. This meta-analysis sought to assess the efficacy and safety of immunotherapy-chemotherapy combinations in mCRPC. Methods A thorough search of Clini...

Full description

Saved in:

Bibliographic Details
Main Authors:	Azka Syed, Hasan Raza, Hameer Khan Khaskheli, Izza Rafique, Sameen Shahid, Nimra Shahzadi, Abdelrahman Sayed Al Komi, Abdullah A. Assiri, Muhammad Abbas Khokhar, Najeeb Ullah Khan
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Series:	BMC Cancer
Subjects:	Metastatic castration-resistant prostatic cancer Immune checkpoint inhibitors Immunotherapy Docetaxel MCRPC
Online Access:	https://doi.org/10.1186/s12885-025-14575-1
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer
by: Maibritt Nørgaard, et al.
Published: (2025-04-01)

Enhancing in Vitro anti-metastatic efficacy and deep penetration into tumor spheroid of docetaxel-loaded liposomes via size optimization for prostate cancer treatment
by: Saksorn Klibaim, et al.
Published: (2025-03-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

SLX1 silencing overcomes Olaparib resistance in metastatic castration-resistant prostate cancer by disrupting SLX4-mediated DNA repair complexes
by: Xin Zhao, et al.
Published: (2025-12-01)

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial
by: Qihua Zou, et al.
Published: (2025-05-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
by: Marina N. Sharifi, et al.
Published: (2025-08-01)

Editorial: Androgen-dependent diseases and their treatment
by: Marisa Cabeza
Published: (2024-12-01)

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis
by: Ying Zhang, et al.
Published: (2025-01-01)

Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014–2024
by: Ahmed H. Zedan, et al.
Published: (2025-04-01)

Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions
by: Lanlan Xiang, et al.
Published: (2025-02-01)

Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer
by: Hejar Atalan, et al.
Published: (2025-06-01)

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
by: Tae Hwan Kim, et al.
Published: (2023-11-01)

Effect of docetaxel administration on fluid dynamics in mice
by: Ayana Mawaki, et al.
Published: (2025-05-01)

Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis
by: Brigida Anna Maiorano, et al.
Published: (2025-02-01)

Metformin-Sensitized Chemotherapy of Docetaxel Nanoemulsions Based on a Sequential Administration
by: Junlei Zhang, et al.
Published: (2025-06-01)

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)

Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
by: Aleymi M. Perez, et al.
Published: (2024-09-01)

Two restraining devices in connection to surgical castration with or without local anesthesia: effects on piglet stress
by: Ann-Helena Hokkanen, et al.
Published: (2025-04-01)

The Use of Lidocaine-Infused Castration Bands to Castrate Beef–Dairy Calves and Its Effect on Animal Welfare and Performance
by: Madeline R. Mancke, et al.
Published: (2025-02-01)

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre‐clinical study
by: Kaan Low, et al.
Published: (2024-09-01)

THERMAL CASTRATION AS A METHOD OF GAMETOPHYTIC SELECTION TO INCREASE ADAPTABILITY
by: A. N. Borovik, et al.
Published: (2018-05-01)

Metformin‐Associated Lactic Acidosis During Docetaxel Therapy for Castration‐Resistant Prostate Cancer: A Case Report
by: Y. Inoue, et al.
Published: (2025-07-01)

Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer
by: Laura Lawaczeck, et al.
Published: (2025-03-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Effect of Curcumin on Docetaxel-Induced Apoptosis in the DU145 (Prostate) Cell Line Using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay
by: Mohammad Shokrzadeh, et al.
Published: (2025-07-01)

Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study
by: Kambiz Rahbar, et al.
Published: (2025-07-01)

Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer
by: Hugo Peslier, et al.
Published: (2025-03-01)

Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study
by: Li DW, et al.
Published: (2025-04-01)

DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)

Therapy results of patients with metastatic castration‑resistant prostate cancer. Regional experience
by: P. G. Berezin, et al.
Published: (2023-03-01)

Engineering Docetaxel Micelles for Enhanced Cancer Therapy Through Intermolecular Forces
by: Hao Wang, et al.
Published: (2024-10-01)